Resources

×

  • Biosimilars

Messaging Playbooks

Monitor Payer Messaging Perception: Oncology...

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in oncology biosimilars.

Webinars

Meet the Expert: Understanding the...

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

P&T Sessions

Immunology Biosimilars: Webcast

MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Will Existing Contracts With...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Do Payers See The...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

Could Manufacturers Entice Payers to...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Will Portfolio Contracting Impact...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Does The Impending Launch...

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

Title

Description